about
Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in miceOn deriving the dose-effect relation of an unknown second component: an example using buprenorphine preclinical dataOxycodone combinations for pain relief.Comparison of human and porcine gastric clasp and sling fiber contraction by M2 and M3 muscarinic receptors.Inhibition of GSK3 attenuates dopamine D1 receptor agonist-induced hyperactivity in miceCombining opioid and adrenergic mechanisms for chronic pain.Combinations of cocaine with other dopamine uptake inhibitors: assessment of additivity.Resveratrol in combination with other dietary polyphenols concomitantly enhances antiproliferation and UGT1A1 induction in Caco-2 cells.Self-administration of drug mixtures by monkeys: combining drugs with comparable mechanisms of actionCombination strategies for pain management.Ethanol and cocaine: environmental place conditioning, stereotypy, and synergism in planarians.Levamisole enhances the rewarding and locomotor-activating effects of cocaine in rats.The use of occupation isoboles for analysis of a response mediated by two receptors: M2 and M3 muscarinic receptor subtype-induced mouse stomach contractionsIntra-VTA CART 55-102 reduces the locomotor effect of systemic cocaine in rats: an isobolographic analysis.Revisiting the isobole and related quantitative methods for assessing drug synergismThe beta-lactam antibiotic, ceftriaxone, attenuates morphine-evoked hyperthermia in rats.Interactions between drugs and occupied receptors.An overview of drug combination analysis with isobolograms.Use of programmable protocol timer and data logger in the monitoring of animal behavior.Cocaine synergism with α agonists in rat aorta: computational analysis reveals an action beyond reuptake inhibition.Self-administration of cocaine-remifentanil mixtures by monkeys: an isobolographic analysis.Quantitation of the contractile response mediated by two receptors: M2 and M3 muscarinic receptor-mediated contractions of human gastroesophageal smooth muscle.Cocaine-induced hyperactivity and sensitization are dependent on GSK3Levamisole and cocaine synergism: a prevalent adulterant enhances cocaine's action in vivo.The determination and application of fixed-dose analgesic combinations for treating multimodal pain.'Null method' determination of drug biophase concentration.The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations.Continuous multimechanistic postoperative analgesia: a rationale for transitioning from intravenous acetaminophen and opioids to oral formulations.Fixed-dose combinations for emerging treatment of pain.Quantitative methods for assessing drug synergism.Statistical analysis of drug-drug and site-site interactions with isobolograms.Midazolam enhances the analgesic properties of dexmedetomidine in the rat.On the quantitation of an agonist with dual but opposing components of action: application to vascular endothelial relaxationPharmacologic methods for identification of receptors.Tramadol and several anticonvulsants synergize in attenuating nerve injury-induced allodynia.pA2 and receptor differentiation: a statistical analysis of competitive antagonism.A novel role of cannabinoids: implication in the fever induced by bacterial lipopolysaccharide.Commentary on neostigmine interactions with non steroidal anti-inflammatory drugs by Miranda et al.Synergistic interaction between the two mechanisms of action of tapentadol in analgesia.Control and oscillation in ligand receptor interactions according to the law of mass action.
P50
Q28165249-B5D6A8AB-3DAE-4D4F-861D-FA4982D5BC69Q33522859-30C4A5FC-B915-44E2-83A6-FAEC7D013783Q33713626-D29B2C4B-D3E7-4910-A811-6A99BC3C7038Q33783928-09D30D24-82A1-4AD2-8123-9790780926BEQ34001519-16D98B42-18C8-419A-82C8-CF60850FC596Q34434307-86C5B079-C30E-45F0-9DD7-6A4BF323D41EQ34984055-D961E040-9A43-4DAA-8C52-CB5CEF634975Q35013544-A6042378-2750-44E6-A1E1-DC2E403D864CQ35029313-7AFA38E6-C115-47AE-A5DF-7932E90B88EDQ35548154-0BB0BC3B-4535-4C66-89A3-66A85B28BCBEQ35619877-A691481D-4492-4C4A-8A0A-E4943DFF5022Q35659644-F19ECB57-8434-4EED-A5C3-B255431C7C0FQ35751766-F06DF95F-0FC3-44B9-B90D-7BDFEEAB33A8Q36013763-A17E0CD1-8C64-42E4-9544-09C752E21BA3Q36057956-87AB9D5F-99AC-4B9C-B112-066E93EED03CQ36094287-FC5CD8FB-1A0E-4AE2-8CA4-566686553B3EQ36099198-ACB24FE9-CDF2-4419-931F-DC6B6C858BA5Q36466884-20C6F407-E1D0-40A9-9DFB-C3C6AEBC83BDQ36659703-138DFA83-EEB1-42EC-9138-1B167F008C7BQ36729413-1A69C439-E3E6-4128-B955-1111C26E94B7Q37154206-DD55BC1F-17F8-4BD6-9577-80583120378DQ37162158-81FAA365-5575-4FF1-AC79-75CACB5CA49EQ37291746-280483AD-953F-4943-9A42-F2A21B267415Q37706827-95AE7820-F19E-402C-81D7-8EF7CD324570Q37719166-36EA0336-956F-42FD-B922-4013D17FFEB2Q37733090-8A78049A-CE5A-4D39-83CB-0F377976C896Q37764985-3715F9A2-2A3D-4660-B743-6D5260288036Q37890040-1D232348-C347-4C14-A1BB-A3A612C9F4A3Q37993955-021A7C49-FFDC-482F-9FC8-861EF1F6E885Q38022020-9EC519D0-3B66-41FD-BDC9-BAB5B0A3B94EQ38699327-66B48F91-6B58-4DCA-BE4D-3F879FF9F7AEQ39032492-ACD53267-ACF4-46C2-9575-578A530BAA21Q39227660-140BA51A-4413-4864-B44C-0B9572C9182EQ39306554-6E2F5F3D-FDE3-48B0-989D-DCAF3853A691Q39334871-E9A5D483-E4B7-493E-A054-84CBBE7CC006Q39813802-B5A666B8-8D47-44A6-8E70-B9149FD4D1FFQ40461241-3D26B419-493C-4027-B98E-D74751B30388Q41768071-5088D60D-BCD4-48AE-B403-7F3B18DBA6D0Q42182000-FA712FF9-9E11-416E-A477-529A53FABF6BQ42479945-C159AFE9-9087-4016-8B7D-C6AAAD4475CE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ronald J. Tallarida
@ast
Ronald J. Tallarida
@en
Ronald J. Tallarida
@es
Ronald J. Tallarida
@nl
Ronald J. Tallarida
@sl
type
label
Ronald J. Tallarida
@ast
Ronald J. Tallarida
@en
Ronald J. Tallarida
@es
Ronald J. Tallarida
@nl
Ronald J. Tallarida
@sl
prefLabel
Ronald J. Tallarida
@ast
Ronald J. Tallarida
@en
Ronald J. Tallarida
@es
Ronald J. Tallarida
@nl
Ronald J. Tallarida
@sl
P106
P1153
7004652573
P21
P31
P496
0000-0002-3760-5076